Patients with Early Stage NSCLC Have a Higher TMB in Comparison to Advanced Stage Disease
Tumour mutational burden and molecular signatures may indicate potential benefit from immunotherapy in early stage non-small cell lung cancer
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome
Findings from an analysis of mutational spectra following radiotherapy
EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC
Advice follows the release of results from the IMpassion131 study
FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
Evidence for efficacy is based on the results from the CheckMate-743 study
EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria
Biosimilar pegfilgrastim received a positive opinion for reducing the duration of neutropenia and the incidence of febrile neutropenia
EMA Recommends Granting a Marketing Authorisation for Melphalan
A new hybrid medicine is intended for the treatment of certain haematological and other cancers and as reduced intensity conditioning treatment prior to allo-HSCT in haematological diseases.
Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later Life Than Counterparts in the General Population
Description of the incidence and risk of co-morbidities developing subsequent to cancer treatment aids in creating tailored survivorship care
EMA Recommends Extension of Indications for Niraparib
New indication concerns maintenance treatment of adults with advanced ovarian cancer who are in response following completion of first-line platinum-based chemotherapy
EMA Recommends Extension of Indications for Atezolizumab
New indication concerns a combination with bevacizumab for the treatment of adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy
EMA Recommends Extension of Indications for Nivolumab and Ipilimumab
New indication concerns their combination with 2 cycles of platinum-based chemotherapy in first-line treatment of metastatic NSCLC without sensitising EGFR mutation or ALK translocation
EMA Recommends Extension of Indications for Olaparib
New indications concern the maintenance treatment in combination with bevacizumab of ovarian cancer with HRD positive status and monotherapy of mCRPC with BRCA1/2 mutations
No Survival Advantage from Radical Hysterectomy in Patients with Cervical Cancer and Intraoperative Detection of Positive Lymph Node Involvement
Whether women with cervical cancer benefit from completion of radical surgery upon intraoperative determination of N1 positivity had been controversial